Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131321) titled 'Clinical Trials of Latency-Reversing Agents and Combined Regimens' on Sept. 1.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University
Condition:
Acquired Immunodeficiency Syndrome
Intervention:
Chidamide monotherapy group:Chidamide 10 mg per dose, administered twice weekly with an interval of no less than 3 days between two doses. Take orally 30 minutes after breakfast for a total treatment duration of 4 weeks.
Combination Group of Chidamide and Metformin:Chidamide 10 mg per dose, twice weekly with...